Neurovascular Transduction During Exercise in Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have
poor exercise capacity and to explore what causes an increase in blood pressure during
exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).
This study will also test whether or not regular exercise on a bicycle and/or treatment with
6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures
during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a
disease called phenylketonuria, but it is not currently FDA approved for blood pressure or
exercise capacity in people with CKD.